cells

Zimberelimab

ZIMBERELIMAB (AB122): A MONOCLONAL ANTIBODY THAT BINDS PD-1 RESTORING THE ANTITUMOR ACTIVITY OF T CELLS

Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. Clinical studies with zimberelimab have demonstrated efficacy and safety that is consistent with currently approved anti-PD-1 therapies.

The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic.

Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options.

ZIMBERELIMAB CLINICAL TRIALS

Non-Small Cell Lung Cancer, PD-L1 Positive (ARC-10)

A randomized Phase 3, open-label, study to evaluate the efficacy of zimberelimab (AB122) monotherapy compared to standard chemotherapy or zimberelimab combined with domvanalimab (AB154) in front-line, PD-L1-positive locally advanced or metastatic non-small cell lung cancer.

Non-small cell lung cancer, PD-L1 positive (ARC-7)

A Phase 2 trial to evaluate the safety and efficacy of zimberelimab monotherapy, domvanalimab + zimberelimab, and domvanalimab + zimberelimab + etrumadenant in front-line non-small cell lung cancer.

Non-small cell lung cancer, EGFRmut (ARC-4)

A Phase 1b trial to evaluate the safety, tolerability, PK, PD, and clinical activity of etrumadenant + carboplatin + pemetrexed ± zimberelimab in EGFR mutant non-squamous non-small cell lung cancer.

Castration-resistant prostate cancer (ARC-6)

A Phase 1b/2 trial to evaluate the efficacy and safety of etrumadenant-based treatment combinations in participants with metastatic castration-resistant prostate cancer.

Pancreatic adenocarcinoma (ARC-8)

A Phase 1 trial to evaluate the safety, tolerability, PD, PK, and clinical activity of AB680 + zimberelimab + nab-paclitaxel + gemcitabine in participants with advanced pancreatic cancer.

Multiple Cancer Types (domvanalimab + Zimberelimab)

A Phase 1b trial to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab ± zimberelimab in participants with advanced solid malignancies.

Colorectal Cancer (ARC-9)

A randomized Phase 1b/2, open-label, multi-center platform study to evaluate the efficacy of etrumadenant (AB928)-based combinations in patients with metastatic colorectal cancer.